<?xml version="1.0" ?>
<document id="7859dc5bc2c21103513a0d3d27e148496c2c617c">
  <chunk id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c0" text="Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats"/>
  <chunk id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1" text="A Target Animal Safety protocol was used to examine adverse events in male and female Fischer F344/NTac rats treated with increasing doses of a subcutaneous implant of a lipid suspension of buprenorphine. A single injection of 0.65 mg/kg afforded clinically significant blood levels of drug for 3 days. Chemistry, hematology, coagulation, and urinalysis values with 2-to 10-fold excess doses of the drug-lipid suspension were within normal limits. Histopathology findings were unremarkable. The skin and underlying tissue surrounding the drug injection were unremarkable. Approximately 25% of a cohort of rats given the excess doses of 1.3, 3.9, and 6.5 mg/kg displayed nausea-related behavior consisting of intermittent and limited excess grooming and self-gnawing. These results confirm the safety of cholesterol-triglyceride carrier systems for subcutaneous drug delivery of buprenorphine in laboratory animals and further demonstrate the utility of lipid-based carriers as scaffolds for subcutaneous, long-acting drug therapy.">
    <entity charOffset="170-175" id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1.e0" ontology_id="CHEBI_18059" text="lipid" type="chemical"/>
    <entity charOffset="190-203" id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1.e1" ontology_id="CHEBI_3216" text="buprenorphine" type="chemical"/>
    <entity charOffset="286-290" id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1.e2" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="538-542" id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1.e3" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="595-601" id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1.e4" ontology_id="CHEBI_34935" text="cohort" type="chemical"/>
    <entity charOffset="828-835" id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1.e5" ontology_id="CHEBI_78059" text="carrier" type="chemical"/>
    <entity charOffset="861-865" id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1.e6" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="878-891" id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1.e7" ontology_id="CHEBI_3216" text="buprenorphine" type="chemical"/>
    <entity charOffset="965-973" id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1.e8" ontology_id="CHEBI_78059" text="carriers" type="chemical"/>
    <entity charOffset="1017-1021" id="7859dc5bc2c21103513a0d3d27e148496c2c617c.c1.e9" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
  </chunk>
</document>
